HR Execs on the Move

A2 Biotherapeutics

www.a2bio.com

 
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Krupalini Balasubramanya
CHRO Profile

Similar Companies

ElevateBio

ElevateBio is accelerating the future of biotechnology. We have a launched a revolutionary new model that integrates innovators, infrastructure and capital to effectively develop cell, gene and related therapies for patients with severe and life-threatening disorders.

Editas Medicine

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We`re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine `Editors`, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we`ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.

Ganeden Biotech

Ganeden Biotech is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

jCyte

jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company`s allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.

Cardiome Pharma

Cardiome Pharma Corp. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.